lundi 23 octobre 2017

Onco Actu du 23 octobre 2017

1. Biologie

‘A handful’ of gene faults can turn a healthy cell cancerous [Cancer Research UK]

Estimate: Nearly 33,000 papers include misidentified cell lines. Experts talk ways to combat growing problem [Retraction Watch]

Bad Cells. So Many Bad Cells. [In the Pipeline]

4.9 Dép., diag. & prono. - Sein

Mammography Use in Portugal: National Health Survey 2014 [CDC]

5.12.6 Immunothérapies - AMM

Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer [NCI]

5.12.8 Immunothérapies - Economie

NICE shoots down Opdivo again, this time in bladder cancer [FierceBiotech]

NICE no for Opdivo in urothelial carcinoma [PharmaTimes]

5.2 Pharma

AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission [AstraZeneca]

Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients [Novartis]

5.3 Traitements - FDA, EMA, NICE...

New action plan to foster development of advanced therapies [EMA]

Unparalleled access to clinical data - one year on [EMA]

FDA releases flurry of new, revised drug-specific guidance documents [EndPoints]

5.4 Traitements - Economie

NICE bars NHS access to Lenvima, Nexavar for thyroid cancer [PharmaTimes]

Taxpayer-funded drugs 'too expensive for patients’ [BBC News]

6.1 Observation

Many Breast Cancer Patients Receive More Radiation Therapy Than Needed [NPR]

6.11 Patients

Cancer Diagnosis Galvanizes a Medical Student [Wall Street Journal]

6.5 Médecines alternatives

UC-Irvine, integrative medicine, and the delusion of being “science-based” [Science-Based Medicine]

6.6 Publications

Ask The Chefs: Where Does Open Access Go From Here? [The Scholarly Kitchen]

6.7.3 DMP

The Curse of Medical Records Documentation [MD Whistleblower]

6.9 Controverses

Rationing care to smokers and the obese will not solve its financial crisis [The Observer]

California judge tosses $417 million talc cancer verdict against Johnson & Johnson [Reuters]